Roche Pharma has introduced India's first subcutaneous immunotherapy for lung cancer, which can be administered in just seven minutes. This marks a significant advancement in cancer treatment, offering a quicker and more convenient alternative to traditional intravenous therapies.
Treatment Details and Cost
Each dose of this immunotherapy costs Rs 3.7 lakh. On average, patients require between three and six dosages, depending on the severity and progression of the disease. The total cost of treatment can therefore range from approximately Rs 11.1 lakh to Rs 22.2 lakh.
How It Works
The therapy is designed to boost the patient's immune system to fight cancer cells more effectively. Unlike conventional treatments that require lengthy hospital visits for intravenous infusion, this subcutaneous injection can be administered quickly in a clinical setting, reducing patient discomfort and saving time.
Impact on Patients
This new treatment option is expected to improve the quality of life for lung cancer patients by minimizing the time spent in hospitals. It also offers a more accessible treatment modality, especially for those who have difficulty commuting or adhering to longer infusion schedules.
Roche Pharma's launch comes at a critical time when lung cancer incidence is rising in India. The therapy is part of a broader effort to bring innovative and patient-friendly cancer treatments to the market.
Experts believe that the introduction of subcutaneous immunotherapy could set a new standard for cancer care in the country, potentially influencing future treatment protocols and healthcare policies.
